Craig Palmer - CVRx Senior Sales
| CVRX Stock | USD 15.32 0.01 0.07% |
Executive
Craig Palmer is Senior Sales of CVRx Inc
| Age | 47 |
| Address | 9201 West Broadway Avenue, Minneapolis, MN, United States, 55445 |
| Phone | 763 416 2840 |
| Web | https://www.cvrx.com |
Craig Palmer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Craig Palmer against CVRx stock is an integral part of due diligence when investing in CVRx. Craig Palmer insider activity provides valuable insight into whether CVRx is net buyers or sellers over its current business cycle. Note, CVRx insiders must abide by specific rules, including filing SEC forms every time they buy or sell CVRx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Craig Palmer over six months ago Disposition of 151 shares by Craig Palmer of CVRx at 0.237 subject to Rule 16b-3 | ||
Craig Palmer over six months ago Disposition of 151 shares by Craig Palmer of CVRx at 0.237 subject to Rule 16b-3 |
CVRx Management Efficiency
The company has return on total asset (ROA) of (0.3144) % which means that it has lost $0.3144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7902) %, meaning that it created substantial loss on money invested by shareholders. CVRx's management efficiency ratios could be used to measure how well CVRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.38 in 2024. Return On Capital Employed is likely to drop to -0.42 in 2024. At this time, CVRx's Net Tangible Assets are fairly stable compared to the past year. Debt To Assets is likely to rise to 0.35 in 2024, whereas Total Assets are likely to drop slightly above 107.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Helen Leupold | Bioventus | N/A | |
| Angeline McCabe | Nevro Corp | N/A | |
| Thomas MBA | Profound Medical Corp | N/A | |
| Aimee Einstein | Si Bone | N/A | |
| Amy Treadwell | Neuropace | N/A | |
| Frank Vizesi | Orthofix Medical | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Niamh Pellegrini | Nevro Corp | 57 | |
| Larry Chen | Bioventus | N/A | |
| Katrina JD | Bioventus | 62 | |
| Anthony Recupero | Si Bone | 65 | |
| Michael Pisetsky | Si Bone | 46 | |
| Jeff Bertolini | Si Bone | N/A | |
| MBA BS | Bioventus | N/A | |
| Michael JD | Si Bone | 46 | |
| Mark Karshner | Orthopediatrics Corp | N/A | |
| David Caraway | Nevro Corp | 63 | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Jill Mason | Orthofix Medical | N/A | |
| Martha MD | Neuropace | 67 | |
| Dylan John | Neuropace | N/A | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.31 |
CVRx Inc Leadership Team
Elected by the shareholders, the CVRx's board of directors comprises two types of representatives: CVRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CVRx. The board's role is to monitor CVRx's management team and ensure that shareholders' interests are well served. CVRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CVRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| RN MBA, Reimbursement, Access | ||
| Nadim Yared, President CEO | ||
| Kevin Hykes, CEO President | ||
| Tonya SPHR, Chief Officer | ||
| Jared Oasheim, Chief Officer | ||
| Paul Verrastro, Chief Officer | ||
| Craig Palmer, Senior Sales | ||
| Jennifer Englund, Senior Affairs | ||
| Robert John, Chief Officer | ||
| Paul Pignato, Vice Operations | ||
| Jonelle Burnham, Vice Counsel | ||
| MSc MD, Chief Officer |
CVRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CVRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (0.97) % | ||||
| Current Valuation | 322 M | ||||
| Shares Outstanding | 24.26 M | ||||
| Shares Owned By Insiders | 4.39 % | ||||
| Shares Owned By Institutions | 71.90 % | ||||
| Number Of Shares Shorted | 2.06 M | ||||
| Price To Earning | 0.19 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CVRx Stock Analysis
When running CVRx's price analysis, check to measure CVRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CVRx is operating at the current time. Most of CVRx's value examination focuses on studying past and present price action to predict the probability of CVRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CVRx's price. Additionally, you may evaluate how the addition of CVRx to your portfolios can decrease your overall portfolio volatility.